NON-HODGKIN'S LYMPHOMA

This early-stage trial tests an experimental oral drug called ABBV-525 in people with B-cell blood cancers like lymphoma and leukemia. The study aims to find a safe dose and check for side effects. About 78 adults will take the drug in different dose groups over up to 64 months.

This phase II trial is testing two drugs, obinutuzumab and ibrutinib, as the first treatment for people with indolent non-Hodgkin's lymphoma, a slow-growing blood cancer. The goal is to see how many patients respond to the combination. The study involves 30 participants and is no…

This early-phase trial tests SC262, a therapy made from donor immune cells (CAR T cells) designed to attack a protein called CD22 on lymphoma cells. It is for people with non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The main goal is to check …

This study tests whether combining copanlisib and rituximab can slow or stop follicular lymphoma, a type of blood cancer, in people who haven't had treatment yet. About 33 participants will receive the drugs through an IV over up to 13 cycles. The goal is to see how many achieve …

This early-phase study tests whether giving a patient's own genetically modified immune cells (CAR T-cells) after high-dose chemotherapy and a stem cell transplant is safe for people with aggressive B-cell non-Hodgkin lymphoma that has returned or not responded to treatment. Seve…

This early-phase study tests a new treatment for people with certain blood cancers (lymphoma or leukemia) that have returned after a stem cell transplant. Researchers take immune cells called T cells from the original stem cell donor, modify them to recognize and attack cancer ce…

This study tests whether giving palifermin and leuprolide acetate can help the immune system recover more quickly after a stem cell transplant for blood cancers like leukemia and lymphoma. About 82 participants will receive these drugs alongside their transplant. The goal is to s…

This study tests a new drug called glofitamab, alone or with another drug (obinutuzumab), in people with B-cell non-Hodgkin's lymphoma that has come back or not responded to previous treatments. The goal is to find the safest and most effective dose and see how well it shrinks tu…

This study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The main goal is to track side effects and safety over a longer period. About 165 participants will continue taking the drug to see how well it works and how safe it…

This early-phase study tests a radioactive imaging drug called 124I-PUH71 in 63 people with non-Hodgkin's lymphoma, myeloma, or solid tumors. The goal is to see how the drug travels through the body and collects in tumors, and how long it stays in the blood. This is not a treatme…